Targeted Covalent Pentafluorobenzene Sulfonamide-Based Afatinib Drug for Treating Breast Cancer

靶向共价五氟苯磺酰胺基阿法替尼药物治疗乳腺癌

• 批准号: 428860
• 负责人: Hekmat Merna
• 金额: $ 1.27万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-12-01 至 2020-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=428860&lang=en
• 关键词: Afatinib Drug; Biophysical Assay; Breast Cancer; Covalent Inhibitors; Drug Discovery; Electrophilic Tuning; Epidermal Growth Factor Receptor; Kinases; Nucleophilic Aromatic Substitution; Pentafluorobenzene Sulfonamide

"Breast cancer is a common malignancy in Canadian women accounting for approximately 14 deaths daily. Although there have been several advancements in treatments, current drugs are plagued by resistance mechanisms and off-target effects which leads to hig

“乳腺癌是加拿大女性的常见恶性肿瘤，每天约有 14 人死亡。尽管治疗方法取得了一些进步，但目前的药物受到耐药机制和脱靶效应的困扰，导致高